drugset / Trial / NCT03150797

Melatonin for Adolescent Migraine Prevention Study

NCT03150797

RandomizedParallel-groupDouble-blindPrevention

Summary

This will be a randomized, multi-site double-blind placebo-controlled trial of melatonin (2 different dosing arms) vs. placebo for migraine prevention in adolescents. We intend to enroll approximately 210 participants over 15 months at two sites: UCLA and UCSF. The duration of participation for each participant will be 4 months.

Timeline

Start
2017-08-02
Primary completion
2019-12-01
Completion
2019-12-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Melatonin Small molecule 3 mg Oral
Subject Melatonin Small molecule 6 mg Oral

Indications